maps glp 1 program Mapping the effectiveness and risks of GLP-1 receptor agonists The expanding landscape of GLP-1

By activating amylin and calcitonin receptors in the brain, particularly within the hypothalamus and brainstem, Cagrilintide reduces food intake, promotes satiety, and contributes to sustained weight loss

Luque MA, Gonzlez N, Mrquez L, et al

Anti-Inflammatory Properties: Chronic inflammation is a risk factor for various cardiovascular diseases

A phase II clinical trial that investigated the efficacy of VK2809 found that participants who received VK2809 exhibited notable reductions in their liver fat contents as determined by the magnetic resonance imaging proton density fat fraction (MRI-PDFF) technique compared with those who received a placebo